Interventional Oncology Market Report 2025

The interventional oncology market size has grown strongly in recent years. It will grow from $2.49 billion in 2024 to $2.72 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth during the historic period can be attributed to the rising incidence of cancer globally, increased adoption of minimally invasive procedures, growing healthcare expenditure in emerging economies, higher demand for image-guided therapies, and heightened awareness of the benefits of interventional oncology.

The interventional oncology market size is expected to see strong growth in the next few years. It will grow to $3.82 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth during the forecast period can be attributed to the rising demand for outpatient oncology procedures, increased use of combination therapies with immuno-oncology, expanding clinical trials for image-guided therapies, greater access to interventional oncology in emerging markets, and the growing role of precision medicine in treatment planning. Major trends expected in the forecast period include advancements in image-guided ablation technologies, development of AI-powered diagnostic tools, innovations in targeted drug-delivery systems, progress in minimally invasive treatment devices, and the emergence of personalized oncology treatment solutions.

The rising prevalence of cancer is expected to drive growth in the interventional oncology market in the coming years. Cancer prevalence refers to the total number of individuals, both newly and previously diagnosed, who are living with a history of cancer at a given point in time. The increase in cancer cases is largely attributed to lifestyle-related risk factors such as poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, which elevate the likelihood of developing various cancers. Interventional oncology supports cancer treatment by offering minimally invasive, targeted therapies that directly focus on tumors. These approaches enhance patient outcomes by reducing harm to healthy tissue and providing faster recovery compared to conventional treatments. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, 160,570 cancer cases were diagnosed in Australia in 2022, representing an increase of 3,789 cases from 156,781 in 2021. Therefore, the growing prevalence of cancer is propelling the expansion of the interventional oncology market.

Companies in the interventional oncology market are developing advanced technologies, such as microcatheter-based embolization systems, to deliver highly precise, targeted cancer therapy while minimizing damage to surrounding healthy tissue. Microcatheter-based embolization systems are medical devices that use small, flexible catheters to deliver embolic agents directly into blood vessels to block or reduce blood flow, typically for the treatment of tumors, vascular malformations, or bleeding. For instance, in March 2025, Terumo Corporation, a Japan-based medical device company, introduced the Occlusafe balloon occlusion catheter as part of its Balloon-TACE (B-TACE) therapy for liver cancer, particularly hepatocellular carcinoma (HCC). This specialized microcatheter utilizes the pressure gradient effect to redirect blood flow and access the microcirculation, allowing higher concentrations of therapeutic agents at the tumor site while minimizing off-target embolization. This targeted method aims to improve clinical outcomes in challenging liver cancer cases by enhancing drug delivery accuracy and providing better visualization during procedures.

In August 2022, Boston Scientific Corporation, a US-based medical device company, acquired Obsidio Inc. for an undisclosed sum. Through this acquisition, Boston Scientific seeks to expand its interventional oncology and embolization portfolio by integrating a distinctive embolic technology that enhances procedural efficiency and enables personalized therapy for patients. Obsidio Inc. is a US-based company specializing in innovative interventional oncology solutions.

Major players in the interventional oncology market are Johnson & Johnson, Siemens Healthineers AG, Stryker Corporation, GE HealthCare Technologies Inc., Boston Scientific Corporation, Terumo Corporation, Hologic Inc., Teleflex Incorporated, Lantheus Holdings Inc., Penumbra Inc., Merit Medical Systems Inc., Guerbet S.A, Asahi Intecc Co. Ltd., AngioDynamics Inc., Sirtex Medical Limited., Delcath Systems Inc., ABK Biomedical Inc., Profound Medical Inc., IceCure Medical Ltd., Minimax Medical Holding Group.

North America was the largest region in the interventional oncology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interventional oncology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the interventional oncology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Interventional oncology is a medical specialty that focuses on minimally invasive, image-guided procedures for the diagnosis and treatment of cancer. Its primary goal is to provide effective cancer therapies with shorter recovery times and fewer side effects compared to traditional surgical approaches.

The primary types of interventional oncology include radiation therapy devices, ablation devices, and embolization devices. Radiation therapy devices are specialized equipment designed to deliver precise doses of ionizing radiation to targeted areas in the body, aiming to destroy or damage abnormal cells while minimizing harm to surrounding healthy tissue. These devices employ technologies such as ultrasound, computed tomography (CT) guidance, and magnetic resonance imaging (MRI) guidance. Procedures performed using these devices include tumor ablation, tumor biopsy, vascular interventions, and palliative care. These treatments are applied to various cancers, including liver, lung, kidney, pancreatic, and prostate cancers, and serve a range of end-users such as hospitals, ambulatory surgical centers, specialty clinics, and research and academic institutions.

The interventional oncology market research report is one of a series of new reports that provides interventional oncology market statistics, including interventional oncology industry global market size, regional shares, competitors with an interventional oncology market share, detailed interventional oncology market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology industry. This interventional oncology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The interventional oncology market consists of revenues earned by entities by providing services such as image-guided tumor ablation, biopsy and diagnostic imaging, pain palliation procedures, and thermal ablation planning and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The interventional oncology market also includes sales of image-guided navigation systems, catheters and guidewires, radiation delivery systems, and biopsy needles and systems. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.